Study guide

3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax

Professional and Linguistic Assessments Board Part 1 PLAB 1

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the PLAB 1 Exam

2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies

1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies

3 Chapter 2: Cardiovascular Medicine & Vascular Disorders

2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease

4 Chapter 3: Respiratory Medicine

3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure

5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery

4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD

6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance

5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies

7 Chapter 6: Endocrinology & Metabolic Medicine

6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease

8 Chapter 7: Neurology & Neurosciences

7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders

9 Chapter 8: Psychiatry & Mental Health

8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health

10 Chapter 9: Obstetrics, Gynaecology & Sexual Health

9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence

11 Chapter 10: Paediatrics & Child Health

10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems

12 Chapter 11: Musculoskeletal Medicine & Rheumatology

11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders

13 Chapter 12: Dermatology, ENT & Ophthalmology

12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer

14 Chapter 13: Haematology, Oncology & Palliative Care

13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral

15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology

14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship

16 Chapter 15: Medical Ethics, Law & UK Clinical Practice

15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse

17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention

18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging

17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays

3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax

Key Takeaways Explain This Topic AI

Pulmonary embolism (PE) risk is stratified using the two-level Wells score: PE unlikely (<= 4 points) warrants a high-sensitivity D-dimer to rule out PE, whereas PE likely (> 4 points) mandates urgent CT Pulmonary Angiography (CTPA) and immediate interim therapeutic anticoagulation.

Haemodynamically stable PE is managed first-line with direct oral anticoagulants (DOACs: apixaban or rivaroxaban); massive PE with haemodynamic instability (SBP < 90 mmHg or cardiac arrest) requires immediate systemic thrombolysis with intravenous alteplase.

Pleural effusions are categorized as transudates (protein < 30 g/L; heart failure, cirrhosis, nephrotic syndrome) or exudates (protein > 30 g/L; malignancy, parapneumonic effusion, PE, TB); Light's criteria resolve borderline protein levels (25-35 g/L).

Empyema or complicated parapneumonic effusion is characterized by pleural fluid pH < 7.2, low glucose (< 3.3 mmol/L), elevated LDH (> 1000 IU/L), or purulent fluid, necessitating prompt ultrasound-guided intercostal chest tube drainage and systemic antibiotics.

Tension pneumothorax produces haemodynamic collapse, distended neck veins, and contralateral tracheal deviation; it is an immediate clinical diagnosis requiring needle decompression (2nd ICS mid-clavicular line) before chest radiography, followed by definitive chest drain insertion.

Last updated: October 2026

3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax

Acute pulmonary vascular emergencies and pleural space disorders represent life-threatening presentations frequently encountered in acute medicine. Rapid clinical risk stratification, prompt diagnostic imaging, and time-critical interventional procedures are vital to prevent fatal decompensation.

1. Pulmonary Embolism (PE): Pathophysiology and Clinical Presentation

Pulmonary embolism occurs when an endogenous or exogenous thrombus—originating in over 90% of cases from the deep veins of the lower limbs or pelvis—migrates through the venous circulation into the pulmonary arterial bed. Obstruction of pulmonary arterial blood flow leads to ventilation-perfusion mismatch (increased dead space), reflex bronchoconstriction, neurohumoral vasoconstriction, acute right ventricular afterload increase, right ventricular dilatation, and potentially fatal circulatory collapse.

Risk Factors (Virchow's Triad)

Endothelial Injury: Recent major surgery (especially hip or knee arthroplasty, pelvic surgery), lower limb trauma, vascular cannulation.

Venous Stasis: Prolonged bed rest, hospital admission, long-distance travel, congestive heart failure, stroke with limb paresis.

Hypercoagulability: Active malignancy, pregnancy, combined oral contraceptive pill or hormone replacement therapy, inherited thrombophilias (Factor V Leiden, prothrombin gene mutation, antithrombin III deficiency), antiphospholipid syndrome.

Clinical Presentation and Findings

Symptoms: Sudden-onset dyspnoea, pleuritic chest pain, haemoptysis (indicates pulmonary infarction), syncope or presyncope (indicates massive PE with acute right heart outflow obstruction).

Physical Signs: Tachypnoea ( RR ≥ 20 /min \text{RR} \ge 20\text{/min} RR ≥ 20 /min ), tachycardia ( HR > 100 bpm \text{HR} > 100\text{ bpm} HR > 100 bpm ), unilateral painful leg swelling (DVT), cyanosis, hypotension (systolic BP < 90 mmHg \text{BP} < 90\text{ mmHg} BP < 90 mmHg ), raised JVP, and right ventricular heave.

Electrocardiogram (ECG): Sinus tachycardia is the most common finding. Classic signs of right ventricular strain include the S 1 Q 3 T 3 S_1Q_3T_3 S 1 ​ Q 3 ​ T 3 ​ pattern (deep S wave in I, pathological Q wave in III, inverted T wave in III), T-wave inversions in leads V1–V4, and new right bundle branch block (RBBB).

2. Two-Level Wells Score & Diagnostic Algorithm

NICE guidelines recommend evaluating all patients with suspected PE using the two-level Wells score :

  • Wells Clinical Feature Score Points
  • Clinical signs and symptoms of DVT (minimum of leg swelling and pain with palpation) 3.0
  • An alternative diagnosis is less likely than pulmonary embolism 3.0
  • Heart rate > 100 beats/min > 100\text{ beats/min} > 100 beats/min 1.5

Immobilization for ≥ 3 consecutive days \ge 3\text{ consecutive days} ≥ 3 consecutive days OR surgery in the past 4 weeks 1.5

  • Previous objectively diagnosed PE or DVT 1.5
  • Haemoptysis 1.0
  • Malignancy (treatment ongoing, within 6 months, or palliative) 1.0
  • Clinical Probability Stratification

PE Unlikely ( ≤ 4 points \le 4\text{ points} ≤ 4 points ):

Perform a high-sensitivity D-dimer test.

Negative D-dimer: PE is safely ruled out; stop investigations and do not anticoagulate.

Positive D-dimer: Arrange an urgent CT Pulmonary Angiography (CTPA) .

PE Likely ( > 4 points > 4\text{ points} > 4 points ):

Arrange an immediate CTPA .

Critical Rule: If CTPA cannot be obtained immediately (e.g., scanner maintenance or night delays), administer interim therapeutic anticoagulation immediately while awaiting imaging.

Imaging Modalities: CTPA vs V/Q Scan

CT Pulmonary Angiography (CTPA): Definitive first-line imaging modality of choice. Directly visualizes intraluminal filling defects in main, lobar, segmental, and subsegmental pulmonary arteries.

Ventilation-Perfusion (V/Q) Scintigraphy: Preferred alternative if:

Severe renal impairment (eGFR < 30 mL/min < 30\text{ mL/min} < 30 mL/min where iodinated contrast is contraindicated).

Severe documented iodinated contrast allergy.

Normal baseline chest X-ray in pregnancy (delivers lower breast radiation dose than CTPA, although CTPA is preferred if the CXR is abnormal).

  • 3. Management of Pulmonary Embolism
  • Haemodynamically Stable PE

First-Line Pharmacotherapy: Direct Oral Anticoagulants ( DOACs ) are first-line per NICE guidelines:

Apixaban: 10 mg 10\text{ mg} 10 mg BD for 7 days, then 5 mg 5\text{ mg} 5 mg BD maintenance.

Rivaroxaban: 15 mg 15\text{ mg} 15 mg BD for 21 days, then 20 mg 20\text{ mg} 20 mg OD maintenance.

Advantage: Single-agent oral therapy without the need for initial low-molecular-weight heparin (LMWH) bridging or INR monitoring.

Alternative Anticoagulation (Special Populations):

Low-Molecular-Weight Heparin (LMWH, e.g., Dalteparin or Enoxaparin): Preferred during pregnancy (DOACs and warfarin are teratogenic/contraindicated). For active cancer , NICE NG158 (2020, updated 2023) now offers a DOAC (apixaban or rivaroxaban) first, with LMWH if a DOAC is unsuitable (for example high-risk gastrointestinal or genitourinary tumours, or interacting chemotherapy).

Unfractionated Heparin (IV UFH): Preferred in severe renal impairment ( CrCl < 15 mL/min \text{CrCl} < 15\text{ mL/min} CrCl < 15 mL/min ) or extreme bleeding risk due to short half-life and reversibility with protamine.

Duration of Anticoagulation:

Provoked PE (identifiable transient risk factor e.g., major surgery, immobilisation): 3 months , then stop if the provoking factor has resolved.

Unprovoked PE: at least 3 months , then consider continuing long-term (NICE NG158) if bleeding risk is acceptable and the person agrees, using a bleeding-risk tool to support the decision.

Active cancer: 3–6 months, then review whether to continue. Antiphospholipid syndrome needs long-term warfarin (DOACs are avoided, especially in triple-positive disease).

Massive PE (Haemodynamically Unstable PE)

Defined by systolic blood pressure < 90 mmHg < 90\text{ mmHg} < 90 mmHg , a drop in systolic BP of ≥ 40 mmHg \ge 40\text{ mmHg} ≥ 40 mmHg for > 15 minutes > 15\text{ minutes} > 15 minutes , or cardiac arrest.

Immediate Intervention: Intravenous systemic thrombolysis with Alteplase (recombinant tPA) ( 50 mg 50\text{ mg} 50 mg bolus in cardiac arrest, or 100 mg 100\text{ mg} 100 mg infused over 2 hours) combined with unfractionated heparin and aggressive hemodynamic resuscitation.

If thrombolysis is contraindicated or fails, consider catheter-directed mechanical thrombectomy or surgical pulmonary embolectomy.

4. Pleural Effusion: Transudate vs. Exudate & Light's Criteria

A pleural effusion is an abnormal accumulation of fluid in the pleural space between the visceral and parietal pleura.

Pathophysiological Distinction

Transudate (Pleural Protein < 30 g/L < 30\text{ g/L} < 30 g/L ): Driven by elevated hydrostatic pressure or decreased oncotic pressure with intact pleural membranes. Pleural surfaces are disease-free.

Causes: Congestive heart failure (most common), liver cirrhosis with ascites (hepatic hydrothorax), nephrotic syndrome, severe hypoalbuminaemia, peritoneal dialysis.

Exudate (Pleural Protein > 30 g/L > 30\text{ g/L} > 30 g/L ): Driven by increased vascular permeability secondary to local pleural inflammation, infection, or malignant infiltration.

Causes: Parapneumonic effusions / empyema, bronchogenic carcinoma, pleural metastases (breast, ovary), pulmonary embolism, tuberculosis, connective tissue disease (rheumatoid arthritis, SLE), pancreatitis.

Light's Criteria (For Borderline Protein: 25 – 35 g/L 25\text{--}35\text{ g/L} 25 – 35 g/L )

When pleural fluid protein is in the borderline zone, Light's criteria reliably separate exudates from transudates. Fluid is classified as an EXUDATE if at least one of the following three criteria is fulfilled:

Pleural Fluid Protein Serum Protein > 0.5 \frac{\text{Pleural Fluid Protein}}{\text{Serum Protein}} > 0.5 Serum Protein Pleural Fluid Protein ​ > 0.5

Pleural Fluid LDH Serum LDH > 0.6 \frac{\text{Pleural Fluid LDH}}{\text{Serum LDH}} > 0.6 Serum LDH Pleural Fluid LDH ​ > 0.6

Pleural Fluid LDH > 2 3 × Upper Limit of Normal for Serum LDH \text{Pleural Fluid LDH} > \frac{2}{3} \times \text{Upper Limit of Normal for Serum LDH} Pleural Fluid LDH > 3 2 ​ × Upper Limit of Normal for Serum LDH

  • Effusion Etiology Protein (g/L) Glucose pH Specific Features
  • Heart Failure < 30 < 30 < 30 (Transudate) Normal > 7.30 > 7.30 > 7.30 Bilateral, clears with loop diuretics

Malignancy > 30 > 30 > 30 (Exudate) Normal or Low Variable Positive cytopathology; often haemorrhagic/blood-stained

Rheumatoid Pleurisy > 30 > 30 > 30 (Exudate) Very Low ( < 1.6 mmol/L < 1.6\text{ mmol/L} < 1.6 mmol/L ) < 7.20 < 7.20 < 7.20 High rheumatoid factor titre, low complement

Tuberculosis > 30 > 30 > 30 (Exudate) Low < 7.30 < 7.30 < 7.30 Lymphocytic predominance ( > 80 % > 80\% > 80% ), high adenosine deaminase (ADA)

Empyema > 30 > 30 > 30 (Exudate) Markedly Low ( < 3.3 mmol/L < 3.3\text{ mmol/L} < 3.3 mmol/L ) Acidic ( < 7.20 \mathbf{< 7.20} < 7.20 ) Frank pus, turbid fluid, LDH > 1000 IU/L \text{LDH} > 1000\text{ IU/L} LDH > 1000 IU/L ; Gram stain positive

Complicated Parapneumonic Effusion and Empyema

A parapneumonic effusion develops secondary to underlying pneumonia. It progresses in three stages: uncomplicated → \rightarrow → complicated → \rightarrow → empyema (frank pus).

Indications for Immediate Intercostal Chest Drain Insertion:

Frankly purulent or turbid fluid (pus).

Pleural fluid pH < 7.20 \text{pH} < 7.20 pH < 7.20 .

Low pleural glucose ( < 3.3 mmol/L < 3.3\text{ mmol/L} < 3.3 mmol/L ) or very high LDH > 1000 IU/L \text{LDH} > 1000\text{ IU/L} LDH > 1000 IU/L .

Positive microbiological culture or Gram stain.

Caution

Antibiotics alone cannot sterilize or resolve an acidic, complicated parapneumonic effusion or empyema. Prompt intercostal tube drainage under thoracic ultrasound guidance is essential to avoid pleural loculation, fibrothorax, and lung entrapment.

5. Pneumothorax: Classification and Management Algorithms

Pneumothorax is the presence of air within the pleural cavity, disrupting the negative intrapleural pressure that maintains lung inflation.

1. Tension Pneumothorax: Emergency Resuscitation

Mechanism: A "one-way valve" laceration in the visceral or parietal pleura allows air into the pleural space during inspiration but prevents exit during expiration. Intrapleural pressure exceeds atmospheric pressure, causing total lung collapse, contralateral mediastinal shift, compression of the vena cava, obstructed venous return, and cardiac arrest.

Clinical Signs: Severe respiratory distress, cyanosis, tachycardia, profound hypotension, distended neck veins (raised JVP), tracheal deviation away from the affected side , hyperresonance to percussion, and absent breath sounds on the affected side.

Emergency Action: Never delay for a chest radiograph! Perform immediate needle thoracostomy / decompression using a large-bore cannula ( 14 – 16 gauge 14\text{--}16\text{ gauge} 14 – 16 gauge ) inserted into:

The 2nd intercostal space in the mid-clavicular line (traditional site), OR

The 4th or 5th intercostal space in the anterior axillary line .

An immediate rush of air confirms decompression; leave the cannula in place and immediately perform definitive intercostal chest drain insertion .

2. Spontaneous Pneumothorax (BTS Guidelines)

Spontaneous pneumothorax is subdivided into Primary Spontaneous Pneumothorax (PSP, occurring in individuals without underlying clinical lung disease) and Secondary Spontaneous Pneumothorax (SSP, occurring in individuals with pre-existing lung pathology, most commonly COPD, asthma, or cystic fibrosis).

Primary Spontaneous Pneumothorax (PSP)

Classically affects young, tall, slender males, especially smokers (including cannabis), secondary to rupture of subpleural apical blebs.

Size is still measured on an erect chest X-ray (rim of 2 cm or more at the hilum is "large"), but the British Thoracic Society (BTS) 2023 guideline bases management on symptoms and high-risk features rather than size alone .

BTS 2023 Approach to Spontaneous Pneumothorax

High-risk characteristics (any of): haemodynamic instability, significant hypoxia, bilateral pneumothorax, underlying lung disease (i.e. SSP), age 50 or over with a significant smoking history, or haemothorax. These patients usually need a chest drain (small-bore, 14 French or less, is preferred).

No high-risk characteristics, minimal symptoms: conservative management is appropriate regardless of size , with safety netting and outpatient review (repeat X-ray at about 2–4 weeks).

No high-risk characteristics, symptoms needing intervention: choose with the patient between ambulatory management (an ambulatory pleural device, where specialist follow-up is available), needle aspiration (16–18 gauge cannula) or a chest drain. If needle aspiration fails, a chest drain or ambulatory device follows.

Secondary Spontaneous Pneumothorax (SSP)

Occurs in patients with underlying lung disease (COPD, severe asthma, pulmonary fibrosis, cystic fibrosis). Because of poor respiratory reserve, even small pneumothoraces can cause respiratory failure.

SSP is itself a high-risk characteristic: patients are admitted , and most need a chest drain ; needle aspiration or an ambulatory device may be considered in selected stable patients, and conservative observation only for very small, minimally symptomatic SSP. Give oxygen to the patient's target saturation (88–92% if at risk of hypercapnia).

Persistent air leak or failure to re-expand (around 3–5 days of drainage) needs early respiratory and thoracic surgical referral; surgery is also offered after a second ipsilateral or first contralateral pneumothorax, and in high-risk occupations (pilots, divers).

Important

Pneumothorax Safety Netting and Lifestyle Restrictions:

Air Travel: Patients must not travel by commercial aircraft until at least 1 week following complete radiographic resolution.

Diving: Underwater SCUBA diving is permanently contraindicated unless the patient has undergone definitive bilateral surgical pleurectomy with normal postoperative lung function.

Loading diagram... British Thoracic Society (BTS) Pneumothorax Management Pathway